Development and Research of Novel Drugs on Oncolytic Viruses and Cancer Immunotherapy
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (1 October 2022) | Viewed by 293
Special Issue Editors
Interests: tumor therapy; oncolytic virus; oncogene; tumor suppressor; tumor immunotherapy; neuroprotection
Special Issue Information
Dear Colleagues,
This Special Issue focuses on the development and testing of various drugs focused on oncolytic viruses and cancer immunotherapy. While providing a unique forum for work in the burgeoning fields of oncolytic virotherapy, as well as T-cell- and stem-cell-based therapies, this Special Issue will consider all top-quality, cutting-edge research that employs innovative molecular and cellular approaches that target cancer cells for destruction, whether by viruses, other microorganisms, vaccination, or by transfer of cells and/or genes.
Prof. Dr. Guangmei Yan
Dr. Jing Cai
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer targeting
- oncolytic virus
- gene therapy
- immunotherapy
- cell-based cancer therapy
- cancer vaccine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
